Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference

Press Release

« Back

Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference

SAN DIEGO, Jun 13, 2011 (GlobeNewswire via COMTEX) --

Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Chief Executive Officer Roger L. Hawley will present an overview of the Company at the 2011 Wells Fargo Securities Healthcare Conference on June 22, 2011, at The InterContinental Hotel in Boston, MA.

Mr. Hawley and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.

   Event: 2011 Wells Fargo Securities Healthcare
    Conference

   Date: Wednesday, June 22, 2011

   Time: 1:00PM ET

   Place: The InterContinental Hotel, Boston, MA

The presentation will be Web cast live and archived for 90 days on Zogenix' Investor Relations Web site at ir.zogenix.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 with its co-promotion partner, Astellas Pharma US, Inc., for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZX002 is a novel, oral, single-entity extended-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.

For additional information, please visit www.zogenix.com.

SUMAVEL(R) and DosePro(R) are registered trademarks of Zogenix, Inc.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Zogenix

CONTACT: INVESTORS:
Zack Kubow | The Ruth Group
646.536.7020 | zkubow@theruthgroup.com
MEDIA:
Jason Rando | The Ruth Group
646.536.7025 | jrando@theruthgroup.com